Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.

Pilar Puerto-CamachoAna Teresa AmaralSalah-Eddine Lamhamedi-CherradiBrian A MenegazHelena Castillo-EcijaJosé Luis OrdóñezSaioa DomínguezCarmen Jordan-PerezJuan Diaz-MartinLaura Romero-PérezMaria Lopez-AlvarezGema Civantos-JuberaMaría José Robles-FríasMichele BiscuolaCristina FerrerJaume MoraBranko CuglievanKeri SchadlerOliver SeifertRoland KontermannKlaus PfizenmaierLaureano SimónMyriam FabreÁngel M CarcabosoJoseph A LudwigEnrique de Álava

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Taken together, these studies demonstrate potent preclinical activity of first-in-class anti-ENG ADCs as a nascent strategy to eradicate Ewing sarcoma.

Keyphrases

cancer therapy
cell therapy
stem cells
drug delivery
anti inflammatory
combination therapy
mesenchymal stem cells
bone marrow
replacement therapy